Douglas Ross, MD
Endocrinology, Diabetes & Metabolism · Boston, MANPI 1831185719
Payments from drug & device makers
Across 21 payments — averaging $143.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- IBSA Pharma Inc.$1K
- GSK$943
- Xeris Pharmaceuticals, Inc.$650
- Novo Nordisk AS$231
Across 8 payments — averaging $227.08 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$1K
- Novo Nordisk$650
What the payments were for
- Consulting fees$2,50083%
- Travel & lodging$2227%
- Food & beverage$2869%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| IBSA Pharma Inc. | 3 | $1,184 |
| GSK | 5 | $943 |
| Xeris Pharmaceuticals, Inc. | 1 | $650 |
| Novo Nordisk AS | 12 | $231 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tirosint$1,125
- Tirosint-SOL$1,125
How this compares
$3,008 in reported general payments places this provider in the 60th percentile of 360 endocrinology, diabetes & metabolism providers in Massachusetts.
See all endocrinology, diabetes & metabolism providers in Massachusetts →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Sandostatin Lar DepotOctreotide Acetate,mi-Spheres | 26 | $90,202 |
| SynthroidLevothyroxine Sodium | 292 | $28,056 |
| Levothyroxine Sodium | 1,121 | $11,052 |
| LevoxylLevothyroxine Sodium | 170 | $6,277 |
| Liothyronine Sodium | 39 | $2,070 |
| Testosterone | 16 | $1,957 |
| Methimazole | 119 | $1,732 |
| Calcitriol | 33 | $1,222 |
| Alendronate Sodium | 72 | $700 |
| Atorvastatin Calcium | 22 | $318 |
| Atenolol | 12 | $58 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in Boston
- David NathanBoston$9M
- Vanita ArodaBoston$4.2M
- George KingBoston$3.7M
- Karen MillerBoston$2.9M
- Steven GrinspoonBoston$2.7M
- Jason GagliaBoston$2.5M
- Elaine YuBoston$1.3M
- Osama HamdyBoston$1.1M
- Steven RussellBoston$1.1M
- Christos MantzorosBoston$983K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.